(2S)-glycidyl-3-nitrobenzenesulfonate | 1314092-54-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: (2S)-glycidyl-3-nitrobenzenesulfonate
• 英文别名: (S)-glycidyl nosylate；(+)-S-glycidyl nosylate；Sulfuric acid, 3-nitrophenyl (2S)-2-oxiranylmethyl ester；(3-nitrophenyl) [(2S)-oxiran-2-yl]methyl sulfate
• CAS: 1314092-54-0
• 化学式: C₉H₉NO₇S
• 分子量: 275.239
• InChiKey: KJJQOOYKYJHKBB-VIFPVBQESA-N

物化性质

• 沸点：
  444.0±41.0 °C(Predicted)
• 密度：
  1.591±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.63
• 重原子数：
  18.0
• 可旋转键数：
  6.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  108.27
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  萘酚 、 (2S)-glycidyl-3-nitrobenzenesulfonate 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 0.5h， 以88%的产率得到S-(+)-Alpha-3-(1-萘氧基)-1,2-环氧丙烷
  参考文献：
  名称：

  Synthesis and Characterization of High-Affinity 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene-Labeled Fluorescent Ligands for Human β-Adrenoceptors

  摘要：

  The growing practice of exploiting noninvasive fluorescence-based techniques to study G protein-coupled receptor pharmacology at the single cell and single molecule level demands the availability of high-quality fluorescent ligands. To this end, this study evaluated a new series of red-emitting ligands for the human beta-adrenoceptor family. Upon the basis of the orthosteric ligands propranolol, alprenolol, and pindolol, the synthesized linker-modified congeners were coupled to the commercially available fluorophore BODIPY 630/650-X. This yielded high-affinity beta-adrenoceptor fluorescent ligands for both the propranolol and alprenolol derivatives; however, the pindolol-based products displayed lower affinity. A fluorescent diethylene glycol linked propranolol derivative (18a) had the highest affinity (log K-D of -9.53 and -8.46 as an antagonist of functional beta 2- and beta 1-mediated responses, respectively). Imaging studies with this compound further confirmed that it can be employed to selectively label the human beta 2-adrenoceptor in single living cells, with receptor-associated binding prevented by preincubation with the nonfluorescent beta 2-selective antagonist 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]-butan-2-ol (ICI 118551) (J. Cardiovasc. Pharmacol. 1983, 5,430-437.)

  DOI：

  10.1021/jm2008562

文献信息

• [EN] BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE<br/>[FR] AGENTS THÉRAPEUTIQUES À BASE DE DÉRIVÉS DU BISPHÉNOL ET MÉTHODES POUR LEUR UTILISATION
  申请人：BRITISH COLUMBIA CANCER AGENCY

  公开号：WO2011082488A1

  公开（公告）日：2011-07-14

  This invention provides compounds having a structure of Formula (I). Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

  本发明提供具有公式（I）结构的化合物。这些化合物的用途包括治疗多种适应症，包括前列腺癌，同时还提供了涉及这些化合物的治疗方法。